Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy

Laura D. Locati, Federica Perrone, Barbara Cortelazzi, Martina Imbimbo, Paolo Bossi, Paolo Potepan, Enrico Civelli, Gaetana Rinaldi, Pasquale Quattrone, Lisa Licitra, Silvana Pilotti

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Androgen-deprivation therapy (ADT) has been reported to be active in androgen receptor (AR)-expressing, relapsed/metastatic (RM), salivary gland cancers (SGCs). Abiraterone, an inhibitor of androgen synthesis, has recently been approved as a second-line treatment in hormone-resistant (HR) prostate cancer (PCa) patients. Two patients with AR-positive HR-RM adenocarcinoma, NOS of the salivary glands have been treated with abiraterone. This is the first time that this agent has been reported to be active in tumors other than HRPCa. Immunohistochemical analysis showed overexpression of EGFR, HER2, and HER3 in both untreated primary tumors. Sequencing analysis revealed a TP53 non-functional mutation in one case and a PIK3CA-activating mutation in the other. In conclusion, second line activity of ADT in AR-expressing, adenocarcinoma, NOS of salivary glands further strengthens the pathogenic and therapeutic role of AR signaling in AR-positive SGCs.

Original languageEnglish
Pages (from-to)678-682
Number of pages5
JournalCancer Biology and Therapy
Volume15
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Androgen Receptors
Salivary Glands
Androgens
Adenocarcinoma
Salivary Gland Neoplasms
Hormones
Therapeutics
Mutation
Neoplasms
Prostatic Neoplasms
abiraterone

Keywords

  • Abiraterone
  • Androgen deprivation therapy
  • Androgen receptor
  • HER3
  • PIK3CA
  • Salivary gland cancers
  • TP53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

@article{92b3a721818649759c2d9abe5991bd60,
title = "Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy",
abstract = "Androgen-deprivation therapy (ADT) has been reported to be active in androgen receptor (AR)-expressing, relapsed/metastatic (RM), salivary gland cancers (SGCs). Abiraterone, an inhibitor of androgen synthesis, has recently been approved as a second-line treatment in hormone-resistant (HR) prostate cancer (PCa) patients. Two patients with AR-positive HR-RM adenocarcinoma, NOS of the salivary glands have been treated with abiraterone. This is the first time that this agent has been reported to be active in tumors other than HRPCa. Immunohistochemical analysis showed overexpression of EGFR, HER2, and HER3 in both untreated primary tumors. Sequencing analysis revealed a TP53 non-functional mutation in one case and a PIK3CA-activating mutation in the other. In conclusion, second line activity of ADT in AR-expressing, adenocarcinoma, NOS of salivary glands further strengthens the pathogenic and therapeutic role of AR signaling in AR-positive SGCs.",
keywords = "Abiraterone, Androgen deprivation therapy, Androgen receptor, HER3, PIK3CA, Salivary gland cancers, TP53",
author = "Locati, {Laura D.} and Federica Perrone and Barbara Cortelazzi and Martina Imbimbo and Paolo Bossi and Paolo Potepan and Enrico Civelli and Gaetana Rinaldi and Pasquale Quattrone and Lisa Licitra and Silvana Pilotti",
year = "2014",
doi = "10.4161/cbt.28410",
language = "English",
volume = "15",
pages = "678--682",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy

AU - Locati, Laura D.

AU - Perrone, Federica

AU - Cortelazzi, Barbara

AU - Imbimbo, Martina

AU - Bossi, Paolo

AU - Potepan, Paolo

AU - Civelli, Enrico

AU - Rinaldi, Gaetana

AU - Quattrone, Pasquale

AU - Licitra, Lisa

AU - Pilotti, Silvana

PY - 2014

Y1 - 2014

N2 - Androgen-deprivation therapy (ADT) has been reported to be active in androgen receptor (AR)-expressing, relapsed/metastatic (RM), salivary gland cancers (SGCs). Abiraterone, an inhibitor of androgen synthesis, has recently been approved as a second-line treatment in hormone-resistant (HR) prostate cancer (PCa) patients. Two patients with AR-positive HR-RM adenocarcinoma, NOS of the salivary glands have been treated with abiraterone. This is the first time that this agent has been reported to be active in tumors other than HRPCa. Immunohistochemical analysis showed overexpression of EGFR, HER2, and HER3 in both untreated primary tumors. Sequencing analysis revealed a TP53 non-functional mutation in one case and a PIK3CA-activating mutation in the other. In conclusion, second line activity of ADT in AR-expressing, adenocarcinoma, NOS of salivary glands further strengthens the pathogenic and therapeutic role of AR signaling in AR-positive SGCs.

AB - Androgen-deprivation therapy (ADT) has been reported to be active in androgen receptor (AR)-expressing, relapsed/metastatic (RM), salivary gland cancers (SGCs). Abiraterone, an inhibitor of androgen synthesis, has recently been approved as a second-line treatment in hormone-resistant (HR) prostate cancer (PCa) patients. Two patients with AR-positive HR-RM adenocarcinoma, NOS of the salivary glands have been treated with abiraterone. This is the first time that this agent has been reported to be active in tumors other than HRPCa. Immunohistochemical analysis showed overexpression of EGFR, HER2, and HER3 in both untreated primary tumors. Sequencing analysis revealed a TP53 non-functional mutation in one case and a PIK3CA-activating mutation in the other. In conclusion, second line activity of ADT in AR-expressing, adenocarcinoma, NOS of salivary glands further strengthens the pathogenic and therapeutic role of AR signaling in AR-positive SGCs.

KW - Abiraterone

KW - Androgen deprivation therapy

KW - Androgen receptor

KW - HER3

KW - PIK3CA

KW - Salivary gland cancers

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=84901717061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901717061&partnerID=8YFLogxK

U2 - 10.4161/cbt.28410

DO - 10.4161/cbt.28410

M3 - Article

VL - 15

SP - 678

EP - 682

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 6

ER -